We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+6.92%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$588M
AUM Growth
+$7.2M
Cap. Flow
-$2.16M
Cap. Flow %
-0.37%
Top 10 Hldgs %
36.51%
Holding
220
New
75
Increased
41
Reduced
27
Closed
76

Top Buys

1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.57M
2
UTHR icon
United Therapeutics
UTHR
+$8.62M
3
INCY icon
Incyte
INCY
+$7.79M
4
COGT icon
Cogent Biosciences
COGT
+$7.05M
5
VKTX icon
Viking Therapeutics
VKTX
+$6.05M

Top Sells

1
REGN icon
Regeneron Pharmaceuticals
REGN
+$7.95M
2
TERN
Terns Pharmaceuticals
TERN
+$6.74M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$4.21M
4
BIOA
BioAge Labs
BIOA
+$4.07M
5
CORT icon
Corcept Therapeutics
CORT
+$3.27M

Sector Composition

1 Healthcare 38.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
1
CALL
Vertex Pharmaceuticals
VRTX
$123B
$41.6M 7.07%
93,100
+4,800
+5% +$2.24M
LQDA icon
2
CALL
Liquidia Corp
LQDA
$7.11B
$25M 4.25%
+662,100
New +$24.6M
UTHR icon
3
CALL
United Therapeutics
UTHR
$22.7B
$23.8M 4.06%
+40,200
New +$20M
VKTX icon
4
CALL
Viking Therapeutics
VKTX
$4.31B
$21.5M 3.65%
659,200
-29,700
-4% -$955K
CAPR icon
5
PUT
Capricor Therapeutics
CAPR
$1.13B
$19M 3.22%
623,400
+423,400
+212% +$11.3M
APGE icon
6
CALL
Apogee Therapeutics
APGE
$10.1B
$18.7M 3.19%
222,500
+11,400
+5% +$828K
VKTX icon
7
Viking Therapeutics
VKTX
$4.31B
$17.1M 2.91%
525,181
+188,332
+56% +$6.05M
UTHR icon
8
United Therapeutics
UTHR
$22.7B
$16.2M 2.75%
27,303
+17,303
+173% +$8.62M
CYTK icon
9
PUT
Cytokinetics
CYTK
$10.9B
$13.2M 2.24%
+200,000
New +$12.7M
JNJ icon
10
Johnson & Johnson
JNJ
$609B
$13.1M 2.24%
53,771
-12,673
-19% -$2.95M
COGT icon
11
Cogent Biosciences
COGT
$6.68B
$12.4M 2.11%
322,764
+190,912
+145% +$7.05M
RVMD icon
12
PUT
Revolution Medicines
RVMD
$39.6B
$12.2M 2.08%
+125,500
New +$12.7M
MRK icon
13
PUT
Merck
MRK
$315B
$12M 2.05%
+100,000
New +$11.5M
UTHR icon
14
PUT
United Therapeutics
UTHR
$22.7B
$11.9M 2.02%
+20,000
New +$9.96M
ABVX
15
CALL
Abivax
ABVX
$11.9B
$11.1M 1.89%
+100,000
New +$11.8M
ABVX
16
PUT
Abivax
ABVX
$11.9B
$11.1M 1.89%
+100,000
New +$11.8M
JAZZ icon
17
Jazz Pharmaceuticals
JAZZ
$15.5B
$10.4M 1.76%
+54,755
New +$9.57M
CAPR icon
18
CALL
Capricor Therapeutics
CAPR
$1.13B
$10M 1.7%
329,300
+17,000
+5% +$453K
INCY icon
19
PUT
Incyte
INCY
$23.4B
$9.92M 1.69%
105,400
+5,400
+5% +$539K
TERN
20
DELISTED
Terns Pharmaceuticals
TERN
$9.58M 1.63%
181,752
-164,128
-47% -$6.74M
KOD icon
21
PUT
Kodiak Sciences
KOD
$2.67B
$9.41M 1.6%
+246,900
New +$6.38M
ROIV icon
22
PUT
Roivant Sciences
ROIV
$24.8B
$9.3M 1.58%
335,800
+17,100
+5% +$439K
BMRN icon
23
BioMarin Pharmaceuticals
BMRN
$11.5B
$8.37M 1.42%
148,229
+1,868
+1% +$109K
ABVX
24
Abivax
ABVX
$11.9B
$8.22M 1.4%
75,944
+300
+0.4% +$35.5K
MRNA icon
25
PUT
Moderna
MRNA
$24.5B
$8.1M 1.38%
+159,400
New +$7.44M
1
2 3 4 5

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
BCM
Blume Capital Management Berkeley, California $588M AUM 29.16% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
BMWS
Brady Martz Wealth Solutions Grand Forks, North Dakota $587M AUM 17.88% 1-Year Est. Return
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return

Diadema Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Diadema Partners held 220 positions worth $588M, up 1.2% from $581M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Diadema Partners's Q1 2026 filing shows 75 new, 41 increased, 27 reduced and 76 closed positions. Its largest new stake was Jazz Pharmaceuticals: 54,755 shares worth $10.4M. The largest sale was Regeneron Pharmaceuticals, an estimated $7.95M.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 29% a quarter earlier.

  • Diadema Partners's largest Q1 2026 buy was Jazz Pharmaceuticals: 54,755 shares worth $10.4M.
  • Diadema Partners added most to United Therapeutics in Q1 2026, an estimated $8.62M increase.
  • Diadema Partners's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $6.74M.
  • Diadema Partners fully exited Regeneron Pharmaceuticals in Q1 2026, selling an estimated $7.95M.
  • Diadema Partners's ten largest holdings make up 37% of its $588M portfolio in Q1 2026.
  • Diadema Partners opened 75 new positions and closed 76 in Q1 2026.
  • Diadema Partners's portfolio value rose 1.2% quarter-over-quarter to $588M.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.